Bruno Despujol’s Post

🌟 Revolutionizing Medicine with DoseMe! 🌟 I had an enlightening conversation with Paul Edwards, the President & CEO of DoseMe, on the latest episode of the Life Science Success Podcast! 🎙️ Here are some key takeaways: Precision in Dosing: DoseMeRx is pioneering precise dosing for critically ill patients, enhancing the efficacy and safety of injectable antibiotics with innovative therapeutic drug monitoring. 💉🔬 Industry Insight: Paul's extensive experience, from leading roles at Merck and GSK to transformative startups, underscores the critical role of real-world data in advancing personalized medicine. 🌍📊 Antimicrobial Stewardship: Emphasizing the importance of antimicrobial stewardship, Paul discusses how DoseMeRx’s technology supports clinicians in delivering the right dose at the right time, improving patient outcomes. 🏥👨⚕️ Future of Medicine: We explored the potential of pharmacogenomics and personalized medicine in shaping the future of healthcare, aiming for treatments tailored to individual patient needs. 🧬🚀 Overcoming Challenges: Addressing current insurance and payment system limitations, Paul highlights the need for systems that better support precision and personalized medicine. 🏛️⚖️ A huge thanks to Paul for sharing his insights and to D3 Digital Media Marketing for sponsoring this episode. Let’s continue to innovate and drive success in life sciences! 👉 Listen to the full episode and join the conversation on advancing healthcare: https://lnkd.in/gn63phKa #LifeScienceSuccess #DoseMeRx #PrecisionMedicine #Pharmacogenomics #DigitalMarketing #HealthcareInnovation #AntimicrobialStewardship

The past year has been a remarkable journey of innovation and insightful discussions sparked by our initial thought leadership article (published November 23rd, 2023). Reflecting on our progress, here are some key highlights: 📈 By the Numbers: - Our articles, featured in esteemed journals like npj Vaccines, Nature Medicine, and Trends in Biotechnology, have garnered over 75,000 accesses collectively. - With over 80 citations, our top articles have received up to 40 citations each. - Achieving remarkable Altmetric scores, our work has secured placements in the 98th and 99th percentiles, showcasing its broad reach and significance. 🔬 Key Highlights: - Our first published article, "Outlook of pandemic preparedness in a post-COVID-19 world" (npj Vaccines), has seen 18,000 accesses and ranks in the 98th percentile on Altmetric. - A more recent publication, "Healthcare on the brink: navigating the challenges of an aging society in the United States" (npj Aging), stands out as our most accessed article with 24,000 accesses, ranking in the 99th percentile. This success underscores the commitment and expertise of my exceptional co-authors which include: Mikael Dolsten, Jane M. True, Verna Welch, Subha Madhavan, Kannan Natarajan, Mike Corbo, Teresa Hauguel, Michelle (Smith) Davitt, PhD, Kelly Lindert, Pirada Suphaphiphat (Allen), B. Adam Williams, Matt Jenkins, Derek MacCormack, Andrew Prigodich, John Androsavich, Nina S., Marie Beitelshees, Andrew Hill and Kristen Prentice. To each contributor, I extend my heartfelt gratitude for your valuable insights, collaboration, and dedication to advancing knowledge in our domain. I would also like to thank Bulmore Consulting for serving as a critical thought partner throughout the entire process. Looking forward, I am enthusiastic about the opportunities ahead as we strive to build on our achievements, explore fresh ideas, and create an even more substantial impact. #ThoughtLeadership #Innovation #Collaboration #Impact #Pfizer

Patient experiences = Human Experiences Love these insights from our very own Pamela Walker Geddes and our client Matyas Lakatos 🙏🏼❤️ I loved our project with Novo Nordisk for diabetes - their ethos around patient centricity and experience aligned so strongly with our values and outlook too! Great insights, felt strongly both as a key partner, but also as the patient that I am these days :) #patientexperience #humanexperience #patientjourneys

The weekly BHI news is live with: 🏆 TEDCO’s 10th Entrepreneur Expo Success – Over 1,000 entrepreneurs, investors, and industry leaders gathered to celebrate Maryland’s entrepreneurial ecosystem at TEDCO’s Expo. 🤝 FDA & Children's National Hospital Collaborate on Pediatric Device Regulation – A new research agreement aims to enhance regulatory science for pediatric and perinatal medical devices. 💉 NextCure, Inc. Advances Phase 1 Trial for Cancer Treatment – FDA approves IND for NextCure’s LNCB74, a promising antibody-drug conjugate targeting multiple cancers. 💼 FY25 MBIA Commercialization Innovation Grant Now Open – Applications open for funding to Maryland-based companies advancing innovation and commercialization efforts. 🏗️ BDC Supports 4MLK Flex Lab Development – Baltimore Development Corporation and Maryland Department of Commerce announce approval of a $200,000 loan for new flex lab space. 🧠 National Cancer Institute (NCI) Webinar on Advancing MRI Metabolic Imaging – Join a December 18 webinar to explore a new MRI technology for enhanced disease detection and monitoring. 💉 Cartesian Therapeutics Reports Positive Phase 2b Results – Positive results from Descartes-08 in myasthenia gravis, with Phase 3 trial details previewed. 🧴 Alphyn Biologics, Inc. Secures U.S. Patent for Atopic Dermatitis Treatment – U.S. Patent Office grants Alphyn a patent for its first-in-class Zabalafin Hydrogel treatment for atopic dermatitis. 🧬 Alithea Genomics Launches DRUG-Seq for Drug Discovery – New RNA sequencing technology unlocks the full potential of transcriptomics for drug discovery. https://lnkd.in/gpfir2W7

📢 Calling all innovators! Don't Miss Your Chance to Join the InnoStars Connect Programme, backed by Europe’s leading pharmaceutical companies. Together with our partner, Chiesi Group, we are looking for groundbreaking solutions in the areas of AIR (respiratory health), RARE (rare and ultrarare diseases), and CARE (neonatology, specialty care and consumer care) related to covered diseases. Innovative Therapeutic Approaches/Solutions: 🔬 Biomarkers – including digital ones for early diagnosis and monitoring 🏥 Medical tools improving patient journey and adherence 💉 Innovative solutions and advanced devices to enhance inhaled drug delivery, as well as complex macromolecule delivery, and for CGT 🌱 Sustainable biotech solutions for therapy and RARE diseases Innovative Digital Health Solutions: 📲 Enhancing patient care and journey experience 🔍 Improving clinical trials: from identification of patients to management and eventual follow-up 📊 Coordinated RW data collection, analysis and use 💪 Boosting treatment outcomes and rehabilitation Don't miss this opportunity to be part of the next wave of healthcare innovation! Learn more and apply by 7 July: https://lnkd.in/dyZ2xfyj #InnoStarsConnect #HealthcareInnovation

🚀 Sergio Andrés Torres Pérez's presentation at Biosimilars LatAm - Colombia 2024 shed light on vital collaborations driving #biosimilars development! In the session "Bridging Borders: A Collaborative Journey in Biosimilars Development, INC-Colombia & UDIBI-Mexico", he highlighted UDIBI's collaboration with the Instituto Nacional De Cancerología E.S.E., emphasizing the importance of local manufacturing for biosimilar products. Such partnerships are key to advancing healthcare accessibility and innovation. 💡🤝 #BiosimilarsLatAm #HealthcareInnovation #Collaboration #BiosimilarsDevelopment

🌟 𝗦𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻𝗶𝗻𝗴 𝗨𝗞 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝘄𝗶𝘁𝗵 𝗚𝗹𝗼𝗯𝗮𝗹 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻! 🌟 Exciting news for the UK’s life sciences sector! At the International Investment Summit, a groundbreaking collaboration between the UK Government and pharmaceutical leader Lilly was announced, promising to revolutionize healthcare and drive economic growth. Here’s what’s in store: 🔬 𝙇𝙖𝙪𝙣𝙘𝙝 𝙤𝙛 𝙇𝙞𝙡𝙡𝙮 𝙂𝙖𝙩𝙚𝙬𝙖𝙮 𝙇𝙖𝙗𝙨: The first European innovation accelerator will provide lab space, mentorship, and funding to support early-stage businesses in developing life-changing therapeutics. 💡𝙁𝙤𝙘𝙪𝙨 𝙤𝙣 𝙊𝙗𝙚𝙨𝙞𝙩𝙮: With obesity costing the NHS over £11 billion annually and being the second-largest preventable cause of cancer, this partnership aims to develop innovative solutions for weight management and other critical health challenges. 💼 𝘽𝙤𝙤𝙨𝙩𝙞𝙣𝙜 𝙩𝙝𝙚 𝙀𝙘𝙤𝙣𝙤𝙢𝙮: The life sciences sector, already supporting 300,000 jobs, will expand further, creating opportunities and driving investment into the UK. This collaboration shows how public-private partnerships can drive impactful change—advancing healthcare innovation and strengthening the UK’s position as a global leader in life sciences. #LifeSciences #HealthcareInnovation #Collaboration #EconomicGrowth #LillyGatewayLabs https://lnkd.in/ecSvMbB4

Looking very much forward to hear the thoughts of the participants on digital endpoints in clinical studies. 👩🔬 #cosinuss #rpm #remotepatientmonitoring #clinicalstudies #pharma #biotech #digitalbiomarkers #digitalhealth #vitalsigns

🔍 Biotech is booming, and Argenx is leading the charge! Are you prepared to tap into one of the fastest-evolving sectors in the market? 🌐 Discover how Argenx's cutting-edge advancements in immunology might redefine investment strategies. 🤔 Their bold moves with antibody-based medicines could mark a turning point for investors. But how do you make sense of these opportunities? ⚖ With upcoming financial reports set to shed light on their growth trajectory, now is the time to reassess your investment approach. 📊 Biotech's appeal lies in its high-risk, high-reward promise—an exciting landscape for the savvy investor. 🚀 Don't miss out on understanding the broader implications and strategies that align with such innovations. 💡 Are you ready to explore these opportunities in the ever-evolving world of biotech? 🧬 Who knows what the future holds for those who take informed strides today? 🤝 #Biotechnology #InvestmentStrategies #InnovateAndInvest 🌟